Login
$RLYB
$15.43 -$0.29 (1.88%) Live

$RLYB SEC Filings

Filed On Filing
12 Nov 2026 425
12 Nov 2026 8-K: Other Events

Rallybio Corporation (the “Company”) announced today that, subject to the satisfaction or waiver of any outstanding closing conditions, it anticipates the transactions contemplated by the Agreement and Plan of Merger and Reorganization (...

10 Nov 2026 425
10 Nov 2026 8-K: Other Events

EAST BERLIN, Conn., November 10, 2026 – Rallybio Corporation (Nasdaq: RLYB) today announced that it will effect a one-for-two reverse stock split of its issued and outstanding common stock in connection with the transactions contemplated...

06 Nov 2026 425
06 Nov 2026 8-K: Other Events

Rallybio Corporation (the “Company”) previously disclosed that, subject to the satisfaction or waiver of any outstanding closing conditions, the Company anticipated the transactions contemplated by the Agreement and Plan of Merger and Re...

05 Nov 2026 Form 4: Mackay Martin, Director

Received 33,224 shares by exercise or conversion ($177K)

05 Nov 2026 Form 4: Hunt Ronald, Director

Received 14,305 shares by exercise or conversion ($63.7K)

04 Nov 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders +1 more

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

03 Nov 2026 Form 4: Lieber Jonathan I, Chief Financial Officer

Received 7,124 shares by exercise or conversion ($106K)

02 Nov 2026 Form 4: Lieber Jonathan I, Chief Financial Officer

Received 21,464 shares by exercise or conversion ($200K)

02 Nov 2026 Form 4: Hunt Ronald, Director

Received 14,820 shares by exercise or conversion ($110K)

30 Oct 2026 Form 4: Nash Christine A, Director

Received 3,562 shares by exercise or conversion ($8.48K)

29 Oct 2026 Form 4: Uden Stephen, Director

Received 33,244 shares by exercise or conversion ($202K)

28 Oct 2026 Form 4: Lieber Jonathan I, Chief Financial Officer

Received 2,500 shares as a grant or award · Sold 599 shares ($9.61K)

28 Oct 2026 Form 4: Chung Wendy, Director

Received 2,062 shares by exercise or conversion ($31.5K)

27 Oct 2026 10-Q
26 Oct 2026 425
26 Oct 2026 8-K: Other Events

As previously disclosed, on May 31, 2026, the Rallybio Corporation, a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Avenzo Therapeutics, Inc., a Delawa...

20 Oct 2026 Form 4: Soteropoulos Paula, Director

Received 3,562 shares by exercise or conversion ($8.48K)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support